The downregulation of GPx3 has been observed in numerous cancers including hepatocellular carcinoma [26], prostate cancer [37], gastric cancer [38], Barrett’s adenocarcinoma [39], glioblastoma [40], and cervical cancer [35]. This evidence concerns the gene GPX3 and prostate cancer.